Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Standard
Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. / Stumm, Laura; Burkhardt, Lia; Steurer, Stefan; Simon, Ronald; Adam, Meike; Becker, Andreas; Sauter, Guido; Minner, Sarah; Schlomm, Thorsten; Sirma, Hüseyin; Michl, Uwe.
in: J CLIN PATHOL, Jahrgang 66, Nr. 7, 7, 2013, S. 563-568.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
AU - Stumm, Laura
AU - Burkhardt, Lia
AU - Steurer, Stefan
AU - Simon, Ronald
AU - Adam, Meike
AU - Becker, Andreas
AU - Sauter, Guido
AU - Minner, Sarah
AU - Schlomm, Thorsten
AU - Sirma, Hüseyin
AU - Michl, Uwe
PY - 2013
Y1 - 2013
N2 - BACKGROUND AND AIMS: Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.METHODS: A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.RESULTS: There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence (p<0.0001; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index (p<0.0001) in all cancers irrespective of ERG fusion status.CONCLUSIONS: These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.
AB - BACKGROUND AND AIMS: Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.METHODS: A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.RESULTS: There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence (p<0.0001; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index (p<0.0001) in all cancers irrespective of ERG fusion status.CONCLUSIONS: These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.
KW - Adenocarcinoma
KW - Aged
KW - Cell Proliferation
KW - Forkhead Transcription Factors
KW - Humans
KW - Immunohistochemistry
KW - In Situ Hybridization, Fluorescence
KW - Ki-67 Antigen
KW - Lymph Nodes
KW - Lymphatic Metastasis
KW - Male
KW - Middle Aged
KW - Neoplasm Grading
KW - Neoplasm Recurrence, Local
KW - Oncogene Proteins, Fusion
KW - Prostate
KW - Prostate-Specific Antigen
KW - Prostatic Neoplasms
KW - Risk Factors
KW - Tissue Array Analysis
KW - Tumor Markers, Biological
U2 - 10.1136/jclinpath-2012-201335
DO - 10.1136/jclinpath-2012-201335
M3 - SCORING: Journal article
C2 - 23559350
VL - 66
SP - 563
EP - 568
JO - J CLIN PATHOL
JF - J CLIN PATHOL
SN - 0021-9746
IS - 7
M1 - 7
ER -